Novartis AG (Novartis AG) Short-Term Debt : $8,339 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Short-Term Debt?

Novartis AG's Short-Term Debt for the quarter that ended in Mar. 2024 was $8,339 Mil.

Novartis AG's quarterly Short-Term Debt increased from Sep. 2023 ($5,458 Mil) to Dec. 2023 ($6,084 Mil) and increased from Dec. 2023 ($6,084 Mil) to Mar. 2024 ($8,339 Mil).

Novartis AG's annual Short-Term Debt declined from Dec. 2021 ($6,227 Mil) to Dec. 2022 ($5,876 Mil) but then increased from Dec. 2022 ($5,876 Mil) to Dec. 2023 ($6,084 Mil).

Novartis AG Short-Term Debt Historical Data

The historical data trend for Novartis AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Short-Term Debt Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

6,846.00

9,591.00

6,227.00

5,876.00

6,084.00

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															6,968.00	8,289.00	5,458.00	6,084.00	8,339.00

Novartis AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Novartis AG Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Novartis AG's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.